



R&D-Products
API PORTFOLIO

January 2024

Pioneering API Distribution since 1963

R&D-Products: APIs

| | |
|------------------------------------|--------------------------------|
| 5-Fluorocytosine | Azilsartan Medoxomil Potassium |
| Abacavir | Balovaptan |
| Abemaciclib | Baloxavir |
| Abiraterone | Baloxavir Marboxil |
| Abrocitinib | Bardoxolone Methyl |
| Acalabrutinib | Baricitinib |
| Acamprosate | Baricitinib Citrate |
| Adrenaline Bitartrate | Bazedoxifene Acetate |
| Afatinib | Bedaquiline Fumarate |
| Afatinib Dimaleate | Belumosudil |
| Afoxolaner | Belumosudil Mesylate |
| Alectinib HCl | Bempedoic Acid |
| Alizapride | Berotrastat HCl |
| Alogliptin | Betrixaban |
| Alogliptin Benzoate | Bictegravir |
| Alpelisib | Bictegravir Sodium |
| Amifampridin Phosphate | Binimetinib |
| Amlodipine | Bisoprolol |
| Ansofaxine HCl | Blonanserin |
| Apabetalone | Bompedoic Acid |
| Apalutamide | Bosutinib |
| Apixaban | Bosutinib Form I |
| Apixaban Amorphous | Bosutinib H2O |
| Aripiprazole Lauroxil | Bremelanotide |
| Armodafinil | Brexiprazole |
| Atogepant | Brigatinib |
| Atorvastatin | Brimonidine |
| Avanafil | Bupivacaine |
| Avatrombopag | Cabotegravir |
| Avatrombopag Maleate | Cabotegravir Sodium |
| Axitinib | Cabozantinib |
| Axitinib Form IV | Cabozantinib Malate |
| Azilsartan Base | Cabozantinib S-Malate |
| Azilsartan Kamedoxomil | Camostat |
| Azilsartan Kamedoxomil Form I | Canagliflozin |
| Azilsartan Medoxomil Monopotassium | Canagliflozin 0.5H2O |

| R&D-Products: APIs | R&D-Products: APIs |
|-------------------------------|---------------------------|
| Cangrelor Tetrasodium | Deuterated Tetrabenazine |
| Cantharidin | Deutetrabenazine |
| Capmatinib | Dextromethorphan HBr H2O |
| Carbozantinib S-Malate | Diphenhydramine |
| Carfilzomib | Diroximel Fumarate |
| Cariprazine | Dolutegravir |
| Caspofungin | Dolutegravir Sodium |
| Cedazuridine | Doravirine |
| Cefovecin | DOTAP |
| Cenobamate | Doxycycline H2O |
| Chlorzoxazone | Doxycycline Hyclate |
| Cobicistat | Duloxetine |
| Copanlisib HCl | Duvelisib |
| Corticotropin Acetate | Dydrogesterone |
| Crisaborole | Edoxaban |
| Crizotinib | Edoxaban Tosylate |
| Dabigatran | Elagolix |
| Dabigatran Etxilate | Elagolix Sodium |
| Dabigatran Etxilate Mesylate | Elexacaftor |
| Dabigatran Mesylate | Eliglustat Hemitartrate |
| Dacomitinib | Eliglustat Tartrate |
| Dapagliflozin | Eltrombopag |
| Dapagliflozin Amorphous | Eltrombopag Olamine |
| Dapagliflozin Premix | Eluxadoline |
| Dapagliflozin Propanediol H2O | Elvitegravir |
| Dapagliflozin SPG Solvate | Elvitegravir Form III |
| Daprodustat | Empagliflozin |
| Darolutamide | Empagliflozin Amorphous |
| Darunavir | Empagliflozin Crystalline |
| Darunavir Amorphous | Enasidenib |
| Dasatinib H2O | Enasidenib Mesylate |
| Degarelix Acetate | Encorafenib |
| Dehydrated Alcohol | Entrectinib |
| Delamanid | Enzalutamide |
| Desvenlafaxine Succinate H2O | Epacadostat |
| Deucravitnib | Epinephrine Bitartrate |

| R&D-Products: APIs | R&D-Products: APIs |
|-----------------------------------|----------------------------|
| Erdafitinib | Glycopyrrolate Tosylate |
| Eribulin | Grapiprant |
| Erlotinib | Guadecitabine |
| Ertugliflozin | Guaifenesin |
| Ertugliflozin L-Pyroglutamic Acid | Ibrexafungerp |
| Erythropoietin | Ibrutinib |
| Erythromycin Ethyl Succinate | Idelalisib |
| Estriol | Indacaterol Acetate |
| Etravirine | Indacaterol Maleate |
| Etravirine Form I | Infigratinib Phosphate |
| Evobrutinib | Ipragliflozin |
| Febuxostat Form A | Isavuconazol |
| Fedratinib | Isavuconozonium |
| Fenfluramine HCl | Islatravir |
| Fenretinide | Ivosidenib |
| Fenticonazole Nitrate | Ixazomib |
| Ferrous Ascorbate | Ixazomib Citrate |
| Ferumoxytol | Ketamine |
| Fexofenadine | Labetalol |
| Fezolinetant | Lactulose |
| Filgotinib Maleate | Laninamivir Octanoate |
| Finerenone | Larotrectinib |
| Flumethrin | Larotrectinib Sulphate |
| Fluralaner | Lasmiditan |
| Folic Acid | Lasmiditan Hemisuccinate |
| Fosaprepitant | Lasmiditan Succinate |
| Fostamatinib | Ledipasvir |
| Fostamatinib Disodium | Lemborexant |
| Fostemsavir | Lenvatinib |
| Gamithromycin | Lenvatinib Mesylate |
| Gefapixant | Lenvatinib Mesylate Form C |
| Gilteritinib | Lenvatinib Mesylate Form M |
| Giredestrant | Lesinurad |
| Glacial Acetic Acid | Lesinurad Sodium |
| Glasdegib | Letermovir |
| Glucagon Acetate | Levobupivacaine HCl |

| R&D-Products: APIs | R&D-Products: APIs |
|-------------------------------|--|
| Levomilnacipran HCl | Netarsudil Dimesylate |
| Lifitegrast | Nilotinib |
| Linaclotide | Nilotinib Fumarate |
| Linaclotide Acetate | Nilotinib HCl |
| Linagliptin | Nilotinib Tartrate |
| Linagliptin Form C | Nintedanib |
| Linzagolix | Nintedanib Esylate |
| Liraglutide | Nintedanib Esylate 0.5H ₂ O |
| Liraglutide Acetate | Niraparib Tosylate |
| Indacaterol Acetate | Nirmatrelvir |
| Lorlatinib | Nitrofurantoin Macrocrystal |
| Losartan | Noradrenaline Bitartrate |
| Lurbinectedin | Octenidine |
| Lusutrombopag | Olaparib |
| Macitentan | Olaparib Form A |
| Maraviroc | Olaparib Form H |
| Maraviroc Potassium | Olodaterol |
| Maraviroc Potassium Amorphous | Olodaterol HCl |
| Maraviroc Potassium Form B | Omadacycline |
| Marbofloxacin | Osimertinib |
| Mavacamten | Osimertinib Mesylate |
| Methocarbamol | Ospemifene |
| Metyrosine | Oteseconazole |
| Micafungin | Ozanimod HCl |
| Migalastat HCl | Ozenoxacin |
| Milrinone Lactate | Palbociclib |
| Mirabegron Alpha Form | Pancrelipase |
| Mirogabalin | Pantoprazole Sodium |
| Mirogabalin Besylate | Patiromer Calcium Sorbitex |
| Mitavipat | Pazopanib |
| Molnupiravir | Pazopanib HCl |
| Naftifine | Peficitinib |
| Naloxegol Oxalate | Pemigatinib |
| Nebivolol | Perampanel |
| Nefazodone | Pergolide |
| Neratinib | Pimavanserin |

| R&D-Products: APIs | R&D-Products: APIs |
|--------------------------------|---|
| Pimavanserin Hemitartrate | Riociguat |
| Pimavanserin Tartrate | Riociguat Modification-I |
| Pioglitazone | Ripretinib |
| Pitolisant | Risdiplam |
| Pitolisant HCl | Ritlecitinib |
| Plinabulin | Ritonavir Hot Melt Extrudate |
| Pomalidomide Form A | Rivaroxaban |
| Ponatinib | Rotigotine Form II |
| Ponatinib HCl | Roxadustat |
| Posaconazole Form I | Rucaparib Camsylate |
| Pralsetinib | Rupatadine Fumarate |
| Pretomanid | Ruxolitinib |
| Primidone | Ruxolitinib Phosphate |
| Propranolol | Sacubitril |
| Pyrotinib Maleate | Sacubitril Sodium |
| Ralinepag | Sacubitril Valsartan |
| Raloxifene | Sacubitril Valsartan Complex |
| Raltegravir | Sacubitril Valsartan Trisodium Hemipentahydrate |
| Raltegravir Form I | Safinamide |
| Raltegravir Form III | Safinamide Methanesulfonate |
| Raltegravir Potassium | Samidorphan |
| Raltegravir Potassium Form III | Sapropterin |
| Regadenoson | Saxagliptin |
| Regadenoson Anhydrous | Saxagliptin H2O |
| Regadenoson H2O | Saxagliptin HCl |
| Regorafenib | Saxagliptin HCl 2H2O |
| Relebactam | Scopolamine Butylbr |
| Relugolix | Selexipag |
| Remdesivir | Selexipag Form I |
| Remimazolam | Selinexor |
| Revefenacin | Selpercatinib |
| Ribociclib Succinate | Selumetinib |
| Rilpivirine | Selumetinib Sulphate |
| Rilpivirine HCl | Semaglutide |
| Rimegepant | Semaglutide Acetate |
| Rimegepant Sulphate | Setmelanotide Acetate |

| R&D-Products: APIs | R&D-Products: APIs |
|------------------------------------|--------------------------------|
| Siponimod | Tildipirosin |
| Siponimod Fumarate | Tivozanib |
| Sitagliptin | Tivozanib HCl H ₂ O |
| Sitagliptin Phosphate | Toceranib |
| Sitagliptin Phosphate Anhydrous | Tofacitinib |
| Sofosbuvir | Tofacitinib Citrate |
| Sofpironium Br | Tolvaptan |
| Solithromycin | Trametinib Dimethyl |
| Solriamfetol HCl | Trametinib Dimethyl Sulfoxide |
| Sotagliflozin | Tranexamic Acid |
| Sotorasib | Trazodone |
| Sparsentan | Trelagliptin |
| Staurosporine | Trientine 2HCl |
| Succinylcholine Chloride | Trifarotene |
| Sulfoxide | Trilaciclib |
| Talazoparib Tosylate | Trilaciclib 2HCl |
| Tapentadol HCl | Triptorelin Acetate |
| Tazemetostat HBr | Tucatinib |
| Teduglutide | Ubrogepant |
| Teduglutide Acetate | Umbrisib |
| Tegaserod Maleate | Umbrisib Tosylate |
| Telotristat | Umeclidinium Br |
| Telotristat Etiprate | Umifenovir HCl |
| Tenapanor | Upadacitinib |
| Tenapanor HCl | Urapidil HCl H ₂ O |
| Teneligliptin HBr H ₂ O | Vadadustat |
| Tenofovir | Valacyclovir |
| Tenofovir Alafenamide Fumarate | Valbenazine |
| Tenofovir Alafenamide Maleate | Varenicline |
| Tepotinib | Vecuronium HBr |
| Tesetaxel | Velpatasvir |
| Tezacaftor | Vemurafenib |
| Thiocolchicoside | Venetoclax |
| Tiagabine HCl | Venglustat |
| Ticagrelor Form II | Vericiguat |
| Tigecycline HCl | Vilanterol |

| R&D-Products: APIs | R&D-Products: APIs |
|------------------------|---------------------|
| Vilanterol Trifenatate | Vonoprazan Fumarate |
| Viloxazine | Voxelotor |
| Vismodegib | Zanubrutinib |
| Voclosporin | Zuranolone |
| Vonoprazan | |

DISCLAIMER FOR PATENTED SUBSTANCES

The Product List contains information on worldwide products, not all of which are available in every country. A reference to any product on this list does not imply that such product is or will be available in your location. Any product referred to on this list may be subject to different regulatory and legal requirements depending on the jurisdiction. Consequently, the Information on this list is not designed or intended as a promotion or advertisement for any product or for the use of any product that is not authorized by the laws and regulations of your jurisdiction.

TIEFENBACHER API & Ingredients reserves the right, in its sole discretion, with respect to the offer of any patented products to: (i) alter the conditions under which it is able to offer any Product; (ii) discontinue the offering of any Product; (iii) discontinue the development of any Product; (iv) withdraw any Product from marketing at any time (whether or not such product has been publicly advertised or announced) as it deems fit to comply with TIEFENBACHER API & Ingredients’s corporate policy and any current legislation as may be amended from time to time.

With respect to the offer of any patented products, a readiness for delivery does only exist for small quantities of the product and exclusively for acts done for experimental purposes according to § 11 no. 2 of the German Patent Act or for studies and experiments which are necessary for obtaining an authorization to place a medicinal product on the market according to § 11 no. 2b of the German Patent Act.



BETTER ACCESS



BETTER QUALITY



BETTER SUPPLY

TIEFENBACHER API + INGREDIENTS GMBH & CO. KG

Van-der-Smissen-Strasse 1-2
22767 Hamburg
Germany

Phone: +49 40 – 36 09 18 – 0
Mail: info@tifi-api.eu

www.tiefenbacher-api.com
A part of TIEFENBACHER GROUP